New drug could shorten hospital stays for rare drug reaction

NCT ID NCT06734884

Not yet recruiting Disease control Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests whether adding benralizumab (a drug already used for asthma) to standard corticosteroid treatment can help people with DRESS syndrome recover faster and spend fewer days in the hospital. DRESS is a rare, severe allergic reaction to certain medications that can damage multiple organs. The study will enroll 96 adults and compare benralizumab injections to a placebo, given alongside usual care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Benralizumab (Fasenra)
What this could lead to: If it works, this could provide a faster recovery from DRESS syndrome and reduce the time patients need to spend in the hospital.
What could go wrong: This is an early Phase 2 trial with only 96 participants, so results may not apply to everyone. Benralizumab also has known side effects, and the added benefit over standard care is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates